Böbrek Bozukluklarında Psikofarmakolojik Tedavi Seçimleri
Özet
Kronik böbrek hastalığı (KBH), farmakokinetik değişiklikler nedeniyle psikofarmakolojik tedavilerde dikkatli ilaç seçimi ve doz ayarlaması gerektiren, morbidite ve mortalitesi yüksek sistemik bir durumdur. Bu hasta grubunda, özellikle böbrek yoluyla atılan lityum, sülpirid ve amisülpirid gibi ilaçların birikim riski bulunduğundan, tedavilere düşük dozda başlanması ve yakın takip yapılması kritik önem taşır. Antipsikotikler metabolik sendrom ve QTc uzaması riskleri yönünden dikkatle seçilmeli, proteine bağlı valproik asit ve karbamazepin gibi duygudurum düzenleyicilerin seviyeleri ise hipoalbüminemi ve ilaç etkileşimleri nedeniyle titizlikle izlenmelidir. KBH ve son dönem böbrek yetmezliği (SDBY) vakalarında, genel popülasyona kıyasla depresyon ve anksiyete gibi psikiyatrik bozukluklar, uyku sorunları (OSAS, huzursuz bacak sendromu) ve hormonal değişimlere bağlı cinsel işlev bozuklukları belirgin şekilde daha sık görülmektedir. Depresyon tedavisinde SSGİ ve SNGİ grubu ajanlar güvenle kullanılabilmekle birlikte, sodyum seviyelerinin izlenmesi ve GFR oranına göre doz azaltımı gerekebilmektedir. Sonuç olarak, KBH hastalarının yaşam kalitesini artırmak, tedavi uyumunu sağlamak ve yüksek intihar riskinin önüne geçebilmek adına çoklu ilaç kullanımları ve yan etkiler gözetilerek kapsamlı psikiyatrik değerlendirmelerin zaman kaybedilmeden yapılması gerekmektedir.
Chronic kidney disease (CKD) is a systemic condition with high morbidity and mortality that requires careful drug selection and dose adjustment in psychopharmacological treatments due to altered pharmacokinetics. In this patient group, since drugs excreted via the renal route such as lithium, sulpiride, and amisulpride carry a risk of accumulation, initiating therapies at low doses and close monitoring are of critical importance. Antipsychotics must be carefully selected regarding metabolic syndrome and QTc prolongation risks, while mood stabilizers like valproic acid and carbamazepine, which bind to proteins, must be meticulously monitored due to hypoalbuminemia and drug interactions. Psychiatric disorders like depression and anxiety, sleep disturbances (OSAS, restless legs syndrome), and sexual dysfunctions due to hormonal changes are observed significantly more frequently in CKD and end-stage renal disease (ESRD) cases compared to the general population. Although SSRI and SNRI group agents can be safely used in depression treatment, monitoring sodium levels and adjusting doses according to the GFR rate may be required. Consequently, to improve the quality of life, ensure treatment adherence, and prevent high suicide risks in CKD patients, it is highly essential to perform comprehensive psychiatric evaluations without losing time, considering polypharmacy and potential adverse effects.
Referanslar
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012; 2:1.
KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'. Kidney Int. 2013;84(3):622-623. doi:10.1038/ki.2013.243
Hallan SI, Coresh J, Astor BC, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006;17(8):2275-2284. doi:10.1681/ASN.2005121273
Bello A, Kawar B, El Kossi M, et al. Epidemiology and pathophysiology of chronic kidney disease. Floege J, Johnson RJ, Feehally J (eds). Comprehensive Clinical Nephrology, 4th edition, 2010, pp: 907-18.
Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One. 2016;11(7):e0158765. Published 2016 Jul 6. doi:10.1371/journal.pone.0158765
Süleymanlar G, Utaş C, Arinsoy T, et al. A population-based survey of Chronic REnal Disease In Turkey--the CREDIT study. Nephrol Dial Transplant. 2011;26(6):1862-1871. doi:10.1093/ndt/gfq656
Soylemezoglu O, Duzova A, Yalçinkaya F, et al. Chronic renal disease in children aged 5-18 years: a population-based survey in Turkey, the CREDIT-C study. Nephrol Dial Transplant. 2012;27 Suppl 3:iii146-iii151. doi:10.1093/ndt/gfs366
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-S266.
Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165-180. doi:10.1016/S0140-6736(11)60178-5
Lederer E, Ouseph R. Chronic kidney disease. Am J Kidney Dis. 2007;49(1):162-171. doi:10.1053/j.ajkd.2006.09.021
U. S. Renal Data System, USRDS 2016 Annual Data Report: Atlas of End Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 2016.
Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975-1982. doi:10.1016/S0140-6736(14)61601-9
Taylor DM, Barnes TR, Young AH. (2021). The Maudsley prescribing guidelines in psychiatry. (14th edition) John Wiley & Sons
Naud J, Nolin TD, Leblond FA, et al. Current understanding of drug disposition in kidney disease. J Clin Pharmacol. 2012;52(1 Suppl):10S-22S. doi:10.1177/0091270011413588
How, P.C., Xiong, G. (2022). Overview of Psychopharmacology Principles in Nephrology. In: Hategan, A., Bourgeois, J.A., Gangji, A.S., Woo, T.K. (eds) Psychonephrology. Springer, Cham. https://doi.org/10.1007/978-3-030-84740-1_5
Cohen LM, Tessier EG, Germain MJ, et al. Update on psychotropic medication use in renal disease. Psychosomatics. 2004;45(1):34-48. doi:10.1176/appi.psy.45.1.34
Zhang F, Xue J, Shao J, Jia L. Compilation of 222 drugs' plasma protein binding data and guidance for study designs. Drug Discov Today. 2012;17(9-10):475-485. doi:10.1016/j.drudis.2011.12.018
Matzke GR, Aronoff GR, Atkinson AJ Jr, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(11):1122-1137. doi:10.1038/ki.2011.322
Sonikian M, Metaxaki P, Papavasileiou D, et al. Effects of interleukin-6 on depression risk in dialysis patients. Am J Nephrol. 2010;31(4):303-308. doi:10.1159/000285110
Cukor D, Rosenthal DS, Jindal RM, et al. Depression is an important contributor to low medication adherence in hemodialyzed patients and transplant recipients. Kidney Int. 2009;75(11):1223-1229. doi:10.1038/ki.2009.51
Navaneethan SD, Vecchio M, Johnson DW, et al. Prevalence and correlates of self-reported sexual dysfunction in CKD: a meta-analysis of observational studies. Am J Kidney Dis. 2010;56(4):670-685. doi:10.1053/j.ajkd.2010.06.016
Shirazian S, Grant CD, Aina O, et al. Depression in Chronic Kidney Disease and End-Stage Renal Disease: Similarities and Differences in Diagnosis, Epidemiology, and Management. Kidney Int Rep. 2016;2(1):94-107. Published 2016 Sep 20. doi:10.1016/j.ekir.2016.09.005
Fischer MJ, Xie D, Jordan N, et al. Factors associated with depressive symptoms and use of antidepressant medications among participants in the Chronic Renal Insufficiency Cohort (CRIC) and Hispanic-CRIC Studies. Am J Kidney Dis. 2012;60(1):27-38. doi:10.1053/j.ajkd.2011.12.033
Troidle L, Watnick S, Wuerth DB, et al. Depression and its association with peritonitis in long-term peritoneal dialysis patients. Am J Kidney Dis. 2003;42(2):350-354. doi:10.1016/s0272-6386(03)00661-9
Kurella M, Kimmel PL, Young BS, et al. Suicide in the United States end-stage renal disease program. J Am Soc Nephrol. 2005;16(3):774-781. doi:10.1681/ASN.2004070550
Stahl SM. (2021) Stahl’s essential psychopharmacology: Prescriber’s guide. (7th ed.) New York: Cambridge University Press; 2021
Preljevic VT, Østhus TB, Os I, et al. Anxiety and depressive disorders in dialysis patients: association to health-related quality of life and mortality. Gen Hosp Psychiatry. 2013;35(6):619-624. doi:10.1016/j.genhosppsych.2013.05.006
Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007;14(1):82-99. doi:10.1053/j.ackd.2006.10.001
McLaren KD, Marangell LB. Special considerations in the treatment of patients with bipolar disorder and medical co-morbidities. Ann Gen Hosp Psychiatry. 2004;3(1):7. Published 2004 Apr 22. doi:10.1186/1475-2832-3-7
Chang CK, Hayes RD, Perera G, et al. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS One. 2011;6(5):e19590. doi:10.1371/journal.pone.0019590
Maung SC, El Sara A, Chapman C, et al. Sleep disorders and chronic kidney disease. World J Nephrol. 2016;5(3):224-232. doi:10.5527/wjn.v5.i3.224
Hui DS, Wong TY, Ko FW, et al. Prevalence of sleep disturbances in chinese patients with end-stage renal failure on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 2000;36(4):783-788. doi:10.1053/ajkd.2000.17664
Novak M, Shapiro CM, Mendelssohn D, et al. Diagnosis and management of insomnia in dialysis patients. Semin Dial. 2006;19(1):25-31. doi:10.1111/j.1525-139X.2006.00116.x
Wijemanne S, Jankovic J. Restless legs syndrome: clinical presentation diagnosis and treatment. Sleep Med. 2015;16(6):678-690. doi:10.1016/j.sleep.2015.03.002
Ali S, Parvathareddy VP, Dave NN. (2022). Sexuality and Sexual Dysfunction in the Renal Patient. In: Hategan, A., Bourgeois, J.A., Gangji, A.S., Woo, T.K. (eds) Psychonephrology. Springer, Cham. https://doi.org/10.1007/978-3-030-84740-1_13
